Journal
METABOLIC BRAIN DISEASE
Volume 25, Issue 3, Pages 305-313Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11011-010-9212-z
Keywords
Zonisamide; Parkinson's disease; MPTP; Western blot analysis; Immunohistochemistry; Behavioral test; Mice
Categories
Funding
- Ministry of Science and Education in Japan [136700627, 13671095]
- Grants-in-Aid for Scientific Research [13671095] Funding Source: KAKEN
Ask authors/readers for more resources
We investigated the therapeutic effect of zonisamide against 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in mice, using Western blot analysis, immunohistochemistry and behavioral test. Our Western blot analysis and immunohistochemical study showed that the post-treatment with zonisamide prevented significantly dopaminergic cell damage, the depletion of tyrosine-hydroxylase (TH) protein levels and the proliferation of microglia in the striatum and/or substantia nigra 8 days after MPTP treatment. Furthermore, our behavioral study showed that the post-treatment with zonisamide attenuated significantly the motor deficits 7 days after MPTP treatment. These results show that zonisamide has the therapeutic effect in the MPTP model of Parkinson's disease (PD) in mice. Our study also demonstrates the neuroprotective effect of zonisamide against dopaminergic cell damage after MPTP treatment in mice. Thus our present findings suggest that therapeutic strategies targeted to the activation of TH protein and/or the inhibition of microglial activation with zonisamide may offer a great potential for restoring the functional capacity of the surviving dopaminergic neurons in individuals affected with PD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available